BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance. Vertex Reports Third Quarter 2025 Financial Results — Total revenue of $3.08 billion, an 11$11.9 to 12.0 billion and total combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now 5.0 to $5.1 billion — — ...